Zdrowie i gospodarka · 24/02/2022
FDA Announces Virtual Public Meeting on Biosimilar User Fee Act Program
The FDA is hosting a virtual public meeting to discuss the final assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act and invite public comments on the topics.